Table 2.

Overview of NE incidence during the study

Patients with NEs, n (%)	Original evaluation cohort (N = 189)	Additional evaluation cohort (N = 36)
Any NE	98 (52)	15 (42)
Grade ≥ 3 NEs	24 (13)	6 (17)
Grade 3	20 (11)	4 (11)
Grade 4	4 (2)	0
Grade 5	0	2 (6)
Serious NEs	31 (16)	7 (19)
Any treatment-related NE	66 (35)	11 (31)
Treatment-related grade ≥ 3 NEs	22 (12)	4 (11)
Grade 3	18 (10)	3 (8)
Grade 4	4 (2)	0
Grade 5	0	1 (3)
Serious treatment-related NEs	27 (14)	5 (14)
NEs leading to dose interruption	29 (15)	5 (14)
NEs leading to permanent discontinuation	9 (5)	3 (8)

NE neurologic event